As demand for biological solutions continues to grow across global agriculture and food production systems, Novonesis is strengthening its manufacturing network through a strategic acquisition in Southeast Asia.

The Denmark-based biosolutions company announced that it has entered into an agreement to acquire a production facility in Rayong, Thailand, for approximately USD 50 million. The investment is designed to expand the company’s manufacturing capacity, enhance supply chain resilience and support future growth across key markets.

According to Novonesis, the acquisition aligns with its long-term strategy to build a more responsive and geographically diversified production network. The facility will complement the company’s existing manufacturing footprint and help meet increasing demand for biosolutions worldwide.

The move is particularly relevant as biological technologies continue to gain traction across the animal nutrition sector. Enzymes, microbial solutions and other biosolutions are playing an increasingly important role in improving feed efficiency, supporting animal performance and helping livestock producers meet sustainability goals.

Commenting on the acquisition, Anders Lund, Chief Operating Officer of Novonesis, said strengthening the company’s production footprint in Southeast Asia is an important part of its GROW strategy, which focuses on building a resilient and responsive supply network to support long-term growth. He noted that expanding manufacturing capabilities in the region will enable Novonesis to move closer to customers in a fast-growing market while delivering greater value through improved production capacity and supply flexibility.

Southeast Asia has become an increasingly important region for agricultural production and food systems, creating new opportunities for suppliers of biological solutions. By expanding its presence in the region, Novonesis aims to strengthen its ability to serve customers locally while supporting global demand through a more robust manufacturing network.

The acquisition reflects a broader industry trend toward investment in production capacity and supply chain security, as companies seek to position themselves closer to growth markets and ensure reliable access to innovative technologies.

For Novonesis, the new facility represents not only an expansion of manufacturing capabilities but also a strategic step toward supporting its long-term growth ambitions in biosolutions.